MedTrace Logo

CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes

NCT03350828 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2025-10-10

No results posted yet for this study

Summary

This is a multicenter, cross-sectional, cohort study which will collect contemporary sweat chloride (SC) values from approximately 5000 Cystic Fibrosis (CF) patients prescribed and currently receiving commercially approved Cystic Fibrosis transmembrane conductance regulator (CFTR) modulator therapies.

Conditions

Sponsors & Collaborators

  • Cystic Fibrosis Foundation

    collaborator OTHER

  • Nicole Hamblett

    lead OTHER

Principal Investigators

  • Edith Zemanick, MD · University of Colorado, Denver

  • Michael Konstan, MD · Case Western Reserve University

  • Nicole Mayer-Hamblett, PhD · Seattle Children's Hospital

Eligibility

Min Age
4 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-15
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03350828 on ClinicalTrials.gov